Research
Mixed
Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.
If you are not getting enough weight loss or side effects from GLP-1s alone, adding an amylin analog (like cagrilintide) to your regimen might help. This combination works through a different mechanism in your brain and gut, leading to significant weight loss (around 20%) and potentially better tolerability.
ModerateSupportsMEDIUM confidence
The combination of cagrilintide with semaglutide (CagriSema) illustrates the power of rational pairing... CagriSema consistently achieves weight reductions of approximately 20–22%... through a mechanistically distinct pathway, which may offer advantages in tolerability or sequencing
Why this rating
Based on Phase 2 and 3 trials.
Source
Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
Ioannis Lempesis et al. · Metabolism Open · 2026
DOI 10.1016/j.metop.2026.100463
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.Moderate
- Oral GLP-1 receptor agonists (e.g., orforglipron) provide comparable efficacy to injectable formulations while improving accessibility by eliminating cold-chain requirements.Moderate
- Body composition-targeted agents (e.g., bimagrumab) preserve or increase lean mass while reducing fat mass, addressing the functional decline associated with rapid weight loss.Moderate
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →